RARE · Ultragenyx Pharmaceutical Inc.
Market Cap
$1.51B
Shares
98.59M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$673M
+20.2%
FY2025
Net Income
-$575M
-1.1%
FY2025
Gross Margin
97.77%
-2.2pp
FY2018
Operating Margin
-79.49%
+16.2pp
FY2025
Diluted EPS
-$5.83
+7.3%
FY2025
Operating Cash Flow
-$466M
-12.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $730M – $760M | $717M | $673M | $560M | $434M | $363.33M | $351.41M | $271.03M | $103.71M | $51.5M | $2.61M | $133K | — | — | — | — | |
| — | $2M | — | — | — | — | — | — | — | $1.15M | $1000 | — | — | — | — | — | |
| — | $68.35M | — | — | — | — | — | — | — | $50.35M | $2.61M | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | 97.77% | 99.96% | — | — | — | — | — | |
| — | $773M | $750M | $698M | $648M | $705.79M | $497.15M | $412.08M | $357.36M | $294M | $231.64M | $183.2M | $114.74M | $45.97M | $27.83M | $12.64M | |
| — | $82M | — | — | — | — | — | — | — | — | — | $64.94M | $33M | $10.81M | $4.45M | $3.34M | |
| — | $351M | $349M | $321M | $310M | $278.14M | $219.98M | $182.93M | $161.52M | $127.72M | $99.91M | $64.94M | $33M | — | — | — | |
| — | $33M | $35M | $36M | $26M | $18.22M | $13.24M | $12.26M | $8.54M | $19.54M | $5.83M | $3.42M | $1.38M | $684K | $444K | $313K | |
| — | $695.12M | — | — | — | — | — | $601.15M | $527.89M | $422.87M | $331.55M | $248.14M | $147.74M | $56.78M | $32.28M | $15.99M | |
| — | -$528M | -$535M | -$536M | -$569M | -$648.92M | -$381.74M | -$330.12M | -$424.17M | -$371.37M | -$328.94M | -$248.01M | -$147.74M | -$56.78M | -$32.28M | -$15.99M | |
| — | — | -79.49% | -95.71% | -131.11% | -178.6% | -108.63% | -121.8% | -408.98% | -721.18% | -12593.49% | -186471.43% | — | — | — | — | |
| — | -$495M | -$500M | -$500M | -$543M | -$630.7M | -$368.5M | -$317.86M | -$415.63M | -$351.84M | -$323.12M | -$244.58M | -$146.35M | -$56.09M | -$31.84M | -$15.67M | |
| — | $23M | $25M | $37M | $27M | $11.07M | $1.93M | $7.04M | $13.24M | $9.54M | $4.07M | $3.79M | $2.32M | $608K | $216K | $1000 | |
| — | — | $1M | -$5M | -$1M | -$1.57M | -$1.69M | $607K | -$787K | -$5.59M | $6.53M | $2.17M | $2.12M | -$3.02M | -$2.79M | -$349K | |
| — | -$582M | -$571M | -$567M | -$609M | -$701.73M | -$452.98M | -$185.36M | -$399.44M | -$197.1M | -$318.34M | -$245.84M | -$145.62M | -$59.8M | — | — | |
| — | $4M | $4M | $2M | -$2M | $5.7M | $1.04M | $1.21M | $3.28M | $514K | -$16.2M | $35K | $0 | $0 | $0 | — | |
| — | -$586M | -$575M | -$569M | -$607M | -$707.42M | -$454.03M | -$186.57M | -$402.73M | -$197.61M | -$302.14M | -$245.87M | -$145.62M | -$59.8M | -$35.07M | -$16.33M | |
| — | — | -85.44% | -101.61% | -139.86% | -194.71% | -129.2% | -68.84% | -388.31% | -383.75% | -11567.34% | -184867.67% | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | -$245.87M | -$145.62M | -$64.61M | -$50.29M | -$19.56M | |
| — | -$586M | -$573M | -$571M | -$599M | -$712.59M | -$456.12M | -$185.73M | -$402.24M | -$192.56M | -$308.72M | -$244.1M | -$146.31M | -$59.99M | -$35.06M | -$16.33M | |
| USD/shares | — | -$5.83 | -$5.83 | -$6.29 | -$8.25 | -$10.12 | -$6.70 | -$3.07 | — | — | — | — | — | — | — | — |
| USD/shares | — | -$5.83 | -$5.83 | -$6.29 | -$8.25 | -$10.12 | -$6.70 | -$3.07 | — | — | — | — | — | — | — | — |
| shares | — | — | 98.6M | 90.5M | 73.5M | 69.91M | 67.8M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 3.58M | 3.12M |
| shares | — | — | 98.6M | 90.5M | 73.5M | 69.91M | 67.8M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M | 36.78M | 28.76M | 3.38M | 1.38M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 8.06×
EV/EBIT
—
Peer median 13.11×
P/E (TTM)
—
Peer median 18.50×
Peer medians compare against the 275 similar-size Biotechnology companies (of 516 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| North America | $377,000,000 | $340,000,000 | $307,000,000 | $281,088,000 | $301,110,000 | $237,666,000 | $86,442,000 | $45,339,000 |
| Latin America | $170,000,000 | $131,000,000 | $77,000,000 | $44,711,000 | $23,636,000 | $12,046,000 | — | — |
| EMEA | $108,000,000 | $80,000,000 | $48,000,000 | $36,369,000 | — | — | — | — |
| Asia Pacific | $18,000,000 | $9,000,000 | $2,000,000 | $1,161,000 | — | — | — | — |
| Japan | — | — | — | — | $0 | $0 | — | — |
| All Other | — | — | — | — | — | — | $5,187,000 | $863,000 |
| Europe | — | — | — | — | $26,660,000 | $21,318,000 | $12,085,000 | $5,293,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $369,000,000 | $285,000,000 | $180,000,000 | $118,927,000 | $77,017,000 | $38,720,000 | $20,221,000 | $9,802,000 |
| Royalty | $304,000,000 | $275,000,000 | $183,000,000 | $21,692,000 | $17,951,000 | $12,995,000 | — | — |
| Collaboration and License | $0 | $0 | $71,000,000 | $222,710,000 | $256,438,000 | $219,315,000 | $83,493,000 | $41,693,000 |
Key facts
CIK
1515673
CUSIP
90400D108
13F (30d)
220 filings
219 filers
Visit website
Investor relations